Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations
Clinical trial NCT04548752 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04548752
- Sponsor
- National Cancer Institute (NCI)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-02-22
- Primary completion
- 2026-10-01
- Enrollment
- 88
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.